Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the first patient ...

The article continued: The number of annual cancer cases is expected to rise by 20% by 2030 and jump by 75% by 2050, ...

GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson's disease ...

Explore MicroStrategy's rise as the largest Bitcoin holder. Learn why MSTR stock may outshine 8% STRK dividends for long-term ...

According to the report, the company claims to have successfully brought back the dire wolf from more than 10,000 years of ...

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...

Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

The 61-year-old pilot killed in a small plane crash over the weekend in New Jersey was the CEO of an oncology-focused biotech company, executives announced. Sonnet BioTherapeutics Holdings Inc.

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce the company ...